Objective
There is increasing awareness that the recently identified cytokine IL-33 is playing a key role in multiple types of infections and pathologies. It has been recently demonstrated that IL-33 is crucial for mounting an efficient immune response against viral infections as it strongly enhances T cell responses with lack of IL-33 leading to failure in virus control. IL-33 production by stromal cells in lymph nodes (LN) and spleen is crucial for efficient viral clearance, however, the precise cellular source and signals involved in secretion of this nuclear alarmin during viral infection are unknown. In addition, it is poorly understood how this cytokine controls antiviral CD8 T cell function. To determine the cellular source of IL-33 during viral infections, we will assess IL-33 production by the different types of stromal cells present in lymph nodes and spleen during acute viral infection. The Luther lab has the expertise and state-of-the-art facilities to perform in situ characterization and in vivo analysis of stromal cell subsets present in these organs, allowing for the identification of the IL-33 producing population. Using IL-33GFP/+ mice will facilitate the identification of the cellular source of IL-33 during viral infections. Moreover, using in vitro cultures we will study the signals regulating IL-33 release as well as its role in T cells function. All together, the work described aims to increase our understanding of the mechanisms underlying stromal IL-33 secretion and its effects on antiviral T cell responses and wishes to broaden our knowledge on the role of stroma cells regulating immune responses. Importantly, this work could have future implications for antiviral treatments, including the development of better strategies for antiviral treatments including vaccines or immunotherapy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pathology
- medical and health sciences clinical medicine emergency medicine graft versus host disease
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences basic medicine physiology homeostasis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1015 LAUSANNE
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.